Quantcast

Latest Oncolytic virus Stories

2010-09-13 06:00:00

SAN FRANCISCO and MONTREAL, Sept. 13 /PRNewswire/ -- Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada. "While these data...

2010-09-08 01:00:00

SAN FRANCISCO and ILLKIRCH, France, Sept. 8 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that they have entered into an exclusive partnership to develop and commercialize JX-594 for the...

cd8dad27a479baca8c6739d65503785a1
2010-08-25 14:27:11

Study suggests potential for new oncolytic therapies A novel mechanism used by adenovirus to sidestep the cell's suicide program, could go a long way to explain how tumor suppressor genes are silenced in tumor cells and pave the way for a new type of targeted cancer therapy, report researchers at the Salk Institute for Biological Studies in the Aug. 26, 2010 issue of Nature. When a cell is under stress, the tumor suppressor p53 springs into action activating an army of foot soldiers that...

2010-08-19 06:00:00

SAN FRANCISCO, Aug. 19 /PRNewswire/ -- Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer, today announced the closing of a fully subscribed private placement financing with aggregate gross proceeds of approximately $8.6 million. Proceeds from this transaction will be used to advance the Company's oncology product platform, led by JX-594, a novel oncolytic agent...

2010-07-07 15:52:30

Scientists have used a genetically reprogrammed herpes virus and an anti-vascular drug to shrink spreading distant sarcomas designed to model metastatic disease in mice "“ still an elusive goal when treating humans with cancer, according to a study in the July 8 Gene Therapy. Less than 30 percent of patients with metastatic cancer survive beyond five years, despite the aggressive use of modern combination therapies, including chemotherapy. This creates a significant need for new sarcoma...

2010-07-07 09:07:00

CINCINNATI, July 7 /PRNewswire-USNewswire/ -- Scientists have used a genetically reprogrammed herpes virus and an anti-vascular drug to shrink spreading distant sarcomas designed to model metastatic disease in mice - still an elusive goal when treating humans with cancer, according to a study in the July 8 Gene Therapy. Less than 30 percent of patients with metastatic cancer survive beyond five years, despite the aggressive use of modern combination therapies, including chemotherapy. This...

2010-06-22 08:00:00

SAN FRANCISCO, June 22 /PRNewswire/ -- Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today announced the appointment of Gregory W. Schafer as senior vice president and chief financial officer. Mr. Schafer will be responsible for the Company's finance, accounting, planning, investor relations and treasury functions. "Greg's finance and operations experience in the life sciences industry make him an ideal fit for Jennerex at this pivotal time for the company," said David...

2010-06-17 06:30:00

CALGARY, June 17 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted its 35th U.S. Patent, # 7,731,951 entitled "Viruses for the Treatment of Cellular Proliferative Disorders." The patent claims cover methods for treating cell proliferative disorders by administering modified vaccinia virus to proliferating cells having an activated Ras-pathway. "This patent provides further coverage with respect to the use of a...

2010-05-27 10:26:38

The use of modified measles virus may represent a new treatment for a childhood brain tumor known as medulloblastoma, according to a new study appearing in Neuro-Oncology. Medulloblastoma is the most common malignant central nervous system tumor of childhood, accounting for about 20 percent of pediatric brain tumors. These tumors are located in the cerebellum, the area of the brain that controls balance and other complex motor functions. Refinements in treatment have increased the 5-year...

2010-05-20 13:00:00

SAN FRANCISCO and WASHINGTON, May 20 /PRNewswire/ -- Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today reported positive results from its Phase 1 dose escalation study evaluating the intravenous (IV) administration of JX-594 to patients with metastatic cancer. The data presented today demonstrated clear dose-related delivery to solid tumors, cancer-targeted replication and gene expression, and anti-cancer effects of JX-594 delivered IV. Choi (necrotic) responses were...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related